Icotinib is a new oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). We report on a 49-year-old man with recurrent lung adenocarcinoma treated with icotinib. The patient obtained a partial remission in 4 weeks that was maintained 14 months. Retrospective examination of EGFR mutations confirmed he had a sensitive mutation (exon 19 deletion). This case supports that icotinib has great efficacy in advanced non-small cell lung cancer with sensitive EGFR mutations.
ZhouC., WuY.L., ChenG., FengJ., LiuX.Q., WangC., ZhangS., WangJ., ZhouS., RenS., LuS., ZhangL., HuC., LuoY., ChenL., YeM., HuangJ., ZhiX., ZhangY., XiuQ., MaJ., YouC.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.Lancet Oncol, 12: 735–742, 2011.
6.
GuanZ., ChenX., WangY., ZhongD.: Metabolite identification of a new antitumor agent icotinib in rats using liquid chromatography/tandem mass spectrometry.Rapid Commun Mass Spectrom, 22: 2176–2184, 2008.
7.
LiuD., JiangJ., HuP., TanF., WangY.: Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry.J Chromatogr B Analyt Technol Biomed Life Sci, 877: 3781–3786, 2009.
8.
YanS., LiZ.: A randomized, double-blind, multicenter phase III trial to evaluate the safety and efficacy of icotinib and gefitinib in advanced NSCLC patients previously treated with chemotherapy.Chinese Clinical Oncology (special issue for abstracts of the 13th annual meeting of the Chinese Society of Clinical Oncology), 13, 2010.
9.
RenG.J., ZhaoY.Y., ZhuY.J., XiaoY., XuJ.S., ShanB., ZhangL.: Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.Chin Med J (Engl), 124: 19–25, 2011.
10.
RobertsP.J., StinchcombeT.E., DerC.J., SocinskiM.A.: Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?J Clin Oncol, 28: 4769–4777, 2010.
